TwitterRSSFacebookDirectors Blog
  Disorders A - Z:   A    B   C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z

Skip secondary menu

Anticonvulsant Screening Program

Reports on the ASP from NANDS Council Working Groups

May 2015 New icon

February 2012

Public Access to Neuroactive & Anticonvulsant Chemical Evaluations - banner
Contacts
John Kehne, Ph.D.
Program Director
john.kehne@nih.gov

Karrah Benson
Program Coordinator
karrah.benson@nih
.gov

Brian Klein, Ph.D.
Scientific Project Manager
Brian.klein@nih.gov

Shamsi Raeissi, Ph.D.
Scientific Project Manager
shamsi.raeissi@nih.gov

Margaret Ochocinska, Ph.D.
Program Specialist
ochocinm@ninds.nih.gov

Resource Links
Meetings and Conferences

American Epilepsy Society (AES)

The Epilepsy Foundation

Overview

The NINDS Anticonvulsant Screening Program (ASP) screens compounds for anti-seizure activity in a battery of well-established rodent seizure models and was designed to encourage and facilitate the discovery of new therapeutic agents for epilepsy. Researchers from academia and industry in the U.S. and abroad submit compounds to the ASP, and screening is performed at a contract facility based at the University of Utah on a blinded and confidential basis and at no cost to the ASP participant. The NINDS ASP staff reports test results to participants and provides advice on future development steps for promising compounds, while protecting confidentiality and intellectual property.

Since its establishment in 1975, the program has made important contributions to the development of several FDA-approved drugs for epilepsy, including felbamate (Felbatol), topirimate (Topamax), lacosamide (Vimpat), and retigabine (Potiga). Historically, ASP focused on identifying symptomatic treatments for seizure disorders. Following recommendations from a working group of the National Advisory Neurological Disorders and Stroke (NANDS) Council in 2012, current directions for the program place added emphasis on refractory epilepsy, epileptogenesis and disease progression, and epilepsy comorbidities.

PANAChE Database

A web-based research tool called PANAChE (Public Access to Neuroactive & Anticonvulsant Chemical Evaluations) provides open access to nonproprietary chemical structures and biological data for compounds previously screened in the ASP, including antiepileptic drugs (AEDs) as well as drugs used for other indications. This database is being populated dynamically, beginning with known drugs in the public domain. Compounds submitted to the ASP for testing are included only with permission from the supplier.

Collapsable minus sign. When the image is clicked on the exposed links that are in bulleted fashion will be hidden. Description of Testing Services

Collapsable minus sign. When the image is clicked on the exposed links that are in bulleted fashion will be hidden. How to Participate

Collapsable minus sign. When the image is clicked on the exposed links that are in bulleted fashion will be hidden. Confidentiality

Last updated June 12, 2015